89391-50-4

Usage

Uses

Used in Pharmaceutical Industry:
Imirestat is used as a therapeutic agent for the treatment of diabetic complications, such as diabetic retinopathy, neuropathy, and nephropathy. Its ability to inhibit aldose reductase and prevent the accumulation of sorbitol makes it a potential treatment option for these conditions.
Used in Preclinical Research:
Imirestat is used as a research tool in preclinical studies to investigate its potential as a therapeutic agent for diabetic complications. These studies aim to further understand the mechanism of action of imirestat and its efficacy in preventing the development and progression of diabetic complications.
Used in Drug Development:
Imirestat is used as a candidate for drug development in the pharmaceutical industry. Its potential as a therapeutic agent for diabetic complications has prompted further research and development to optimize its formulation, delivery, and safety profile for clinical use.

Upstream product

• 24313-53-9 2,7-difluoro-9-fluorenone 

Relevant academic research and scientific papers

Spiro-tricyclicaromatic succinimide derivatives

Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome. A particularly preferred class of compounds comprise difluoro-dialkoxy substituted spiro-(9H-fluorene-9,4'-imidazolidine)-2,40 ,5-diones.

Spiro-tricyclicaromatic succinimide derivatives

Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia, in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome.

Treatment of diabetic complications with certain spiro-imidazolidine-diones

Inhibition of aldose reductase activity with tetracyclic spiro-hydantoins, new tetracyclic spirohydantoin derivatives useful in the treatment of complications arising from diabetes mellitus, and a process for preparing spiro-imidazolidine-diones by reacting a mono- or di-fluorofluorene with an excess of oxygen and a tetralkyl- or arylalkyl-trialkyl-ammonium hydroxide are disclosed.

Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase

Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia, in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome.

Method of inhibiting aldose reductase activity

Inhibition of aldose reductase activity with tetracyclic spiro-hydantoins.

Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds

Inhibition of aldose reductase activity with tetracyclic spiro-hydantoins, new tetracyclic spirohydantoin derivatives useful in the treatment of complications arising from diabetes mellitus, and a process for preparing spiro-imidazolidine-diones by reacting a mono- or di-fluorofluorene with an excess of oxygen and a tetralkyl- or arylalkyl-trialkyl-ammonium hydroxide are disclosed